Axon Enterprise’s (AXON) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Axon Enterprise (NASDAQ:AXON) in a report published on Wednesday,Benzinga reports. The firm currently has a $600.00 price target on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the company. JMP Securities reaffirmed an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. Northland Securities increased their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. The Goldman Sachs Group raised their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Robert W. Baird upped their price objective on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $561.31.

Axon Enterprise Trading Up 15.3 %

Shares of NASDAQ AXON opened at $572.40 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $43.65 billion, a PE ratio of 147.91, a PEG ratio of 5.17 and a beta of 1.05. Axon Enterprise has a twelve month low of $265.32 and a twelve month high of $715.99. The stock has a fifty day simple moving average of $613.42 and a 200-day simple moving average of $522.06.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 2,304 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the sale, the insider now owns 128,542 shares of the company’s stock, valued at approximately $84,168,016.18. This trade represents a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,711 shares of company stock valued at $5,631,561. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds have recently made changes to their positions in the company. Allworth Financial LP boosted its position in shares of Axon Enterprise by 7.1% in the 3rd quarter. Allworth Financial LP now owns 1,006 shares of the biotechnology company’s stock valued at $402,000 after purchasing an additional 67 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Axon Enterprise by 23.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,329 shares of the biotechnology company’s stock valued at $2,502,000 after buying an additional 1,196 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Axon Enterprise by 35.7% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 12,422 shares of the biotechnology company’s stock valued at $4,964,000 after acquiring an additional 3,269 shares during the period. DekaBank Deutsche Girozentrale grew its position in shares of Axon Enterprise by 1.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 22,812 shares of the biotechnology company’s stock worth $8,948,000 after acquiring an additional 362 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Axon Enterprise by 6.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the biotechnology company’s stock worth $1,512,000 after acquiring an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.